Days after resigning to join the law firm of Hunton & Williams, FDA chief counsel Sheldon Bradshaw took advantage of his sudden freedom to strongly urge the generic drug industry to support user fees as the best means for reducing the review backlog at the agency. More funding for this from the administration is unlikely, he said.
From the November 01, 2007 Issue of MM+M - Medical Marketing and Media
